Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Dopa for hereditary spastic paraplegia
2004-004509-11Phase 3Active
- Sponsor
- Ulm University
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of levodopa and carbidopa in hereditary spastic paraplegia (HSP), sponsored by Ulm University. Primary endpoints: Effect on spasticity, Effect on mobility and 3 more. Started Sep 2005; status: active.
02
Drugs
levodopacarbidopa
03
Conditions
hereditary spastic paraplegia (HSP)
Beyond the preview
Go deeper on 2004-004509-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004509-11.